Bengaluru: MedGenome has introduced the launch of MetaSeq, a complicated blood take a look at designed to allow quicker and extra complete detection of bloodstream infections (BSIs). The take a look at delivers ends in roughly 5 days and has demonstrated larger sensitivity than customary blood tradition strategies, supporting clinicians in making earlier and extra knowledgeable remedy selections—significantly for critically in poor health and immunocompromised sufferers, the place well timed intervention is essential.
MetaSeq leverages metagenomic next-generation sequencing (NGS) to analyse microbial cell-free DNA (cfDNA) current within the bloodstream. This strategy allows the identification of over 1,400 clinically related pathogens—together with micro organism, fungi, parasites, and DNA viruses—by way of a single take a look at, eliminating the necessity for a number of focused assays.
Conventionally, bloodstream infections are identified utilizing blood tradition exams, which might take a number of days and infrequently yield false-negative outcomes, particularly in sufferers who’ve already obtained antibiotics. MetaSeq overcomes these limitations by detecting microbial DNA instantly from blood samples, enabling correct pathogen identification even when conventional strategies are inconclusive.
MetaSeq is CE-IVD validated for peripheral blood samples and can be carried out on different scientific pattern varieties, together with cerebrospinal fluid, synovial fluid, and ascitic fluid.
Commenting on the launch, Vedam Ramprasad, PhD, CEO, MedGenome Labs Ltd, stated, “Diagnosing bloodstream infections stays one of the crucial difficult elements of scientific care. Physicians are sometimes pressured to depend on symptom-based provisional diagnoses and probability-driven remedy selections, resulting in extended therapies, repeated testing, and delays in administering the proper remedy.”
He added that the superior blood take a look at allows early and correct prognosis by way of genomics-driven, actionable insights.
“MetaSeq transforms scientific decision-making by offering exact diagnostic visibility earlier within the care pathway, empowering clinicians with well timed and dependable info and in the end enhancing affected person outcomes. With MetaSeq, we’re elevating the benchmark for velocity, sensitivity, and reliability in infectious illness diagnostics in India,” he stated.
MedGenome developed MetaSeq in partnership with Noscendo, a Germany-based firm specialising in software-driven pathogen diagnostics. The take a look at is powered by Noscendo’s DISQVER® platform, which employs superior bioinformatics algorithms for correct pathogen identification. DISQVER® is recognised by the World Well being Organisation (WHO) as the one clinically authorised NGS platform for diagnosing invasive fungal illnesses.
Andreas Käpplein, CEO, Noscendo, stated, “This collaboration between MedGenome and Noscendo has the potential to revolutionise an infection diagnostics in South Asia. With exact pathogen identification, MetaSeq lays the muse for quicker and extra correct prognosis of infections. In essential circumstances, this could considerably enhance remedy outcomes and even save lives. Sufferers throughout India can now profit from these developments.”
Source link
#MedGenome #launches #MetaSeq #detect #pathogens #single #blood #take a look at
